TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of Culturaly Adapted Family Intervention for Psychosis
Brief Summary: Aim:

To assess the feasibility of culturally adapted Family Intervention for Psychosis.

Design:

Randomized Control Trial

Setting:

psychiatric department of different hospitals

Participants:

A total of 36 caregivers of Psychosis patients will be randomized to psychological Intervention and treatment as usual arm.

Intervention:

Culturally Adapted Family Intervention for Psychosis

Outcome measure:

Positive and Negative syndrome scale (PANSS) Experience of care -giving inventory(ECI) Care Well-Being \& Support(CWS)


Options:
A: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: The TEA intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The TEA intervention; Assigned to Arm(s): intervention
B: Arm Label: Abangane Support Group; Type: EXPERIMENTAL; Interventions: Behavioral: Abangane Support Group | Arm Label: Wait List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Abangane Support Group; Assigned to Arm(s): Abangane Support Group
C: Arm Label: Family Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Family intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family intervention; Assigned to Arm(s): Family Intervention
D: Arm Label: Parenting for Lifelong Health; Type: OTHER; Interventions: Behavioral: Parenting for Lifelong Health for Young Children | Intervention Type: BEHAVIORAL; Name: Parenting for Lifelong Health for Young Children; Assigned to Arm(s): Parenting for Lifelong Health

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD
Brief Summary: The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.


Options:
A: Arm Label: Active drug group; Type: EXPERIMENTAL; Interventions: Drug: Drug: PRC-063, Drug: PRC-063 | Intervention Type: DRUG; Name: Drug: PRC-063; Assigned to Arm(s): Active drug group | Intervention Type: DRUG; Name: PRC-063; Assigned to Arm(s): Active drug group
B: Arm Label: NT0102; Type: EXPERIMENTAL; Interventions: Drug: NT0102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NT0102; Assigned to Arm(s): NT0102 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: open label PR OROS methylphenidate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: double blind PR OROS methylphenidate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: double blind placebo | Intervention Type: DRUG; Name: double blind placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: double blind PR OROS methylphenidate; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: open label PR OROS methylphenidate; Assigned to Arm(s): 001
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Low Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Medium Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: High Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Low Dose Methylphenidate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medium Dose Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): High Dose Methylphenidate

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Brief Summary: The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.


Options:
A: Arm Label: Dual Task Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dual Task Group | Arm Label: Single Task Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Single Task Group | Intervention Type: BEHAVIORAL; Name: Dual Task Group; Assigned to Arm(s): Dual Task Group | Intervention Type: BEHAVIORAL; Name: Single Task Group; Assigned to Arm(s): Single Task Group
B: Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Behavioral: No Intervention | Arm Label: Vigorous Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Vigorous Exercise | Arm Label: Moderate Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Moderate Exercise | Intervention Type: BEHAVIORAL; Name: Moderate Exercise; Assigned to Arm(s): Moderate Exercise | Intervention Type: BEHAVIORAL; Name: Vigorous Exercise; Assigned to Arm(s): Vigorous Exercise | Intervention Type: BEHAVIORAL; Name: No Intervention; Assigned to Arm(s): Control Group
C: Arm Label: CVT-301 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: CVT-301 Low Dose | Arm Label: CVT-301 High Dose; Type: EXPERIMENTAL; Interventions: Drug: CVT-301 High Dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CVT-301 Low Dose; Assigned to Arm(s): CVT-301 Low Dose | Intervention Type: DRUG; Name: CVT-301 High Dose; Assigned to Arm(s): CVT-301 High Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Isradipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isradipine | Arm Label: Placebo (for Isradipine); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Isradipine) | Intervention Type: DRUG; Name: Isradipine; Assigned to Arm(s): Isradipine | Intervention Type: DRUG; Name: Placebo (for Isradipine); Assigned to Arm(s): Placebo (for Isradipine)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study is to compare between oral misoprostol in solution and vaginal dinoprostone in induction of labour in primiparous women with singleton pregnancy as regards efficiency and safety to both mother and fetus.


Options:
A: Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: dinoprostone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dinoprostone | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: DRUG; Name: Dinoprostone; Assigned to Arm(s): dinoprostone
B: Arm Label: Oral Titrated Misoprostol Solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Vaginal Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Oral Titrated Misoprostol Solution | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Vaginal Misoprostol
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1, 2
D: Arm Label: Oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Vaginal misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Oral misoprostol, Vaginal misoprostol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study
Brief Summary: The purpose of this study is to demonstrate the treatment success of fexinidazole, at one year follow-up visit, in HAT stage 1 and early stage 2 patients.


Options:
A: Arm Label: Fexinidazole; Type: EXPERIMENTAL; Interventions: Drug: Fexinidazole | Intervention Type: DRUG; Name: Fexinidazole; Assigned to Arm(s): Fexinidazole
B: Intervention Type: DRUG; Name: Eflornithine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nifurtimox; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Nifurtimox-Eflronithine Combination Treatment (NECT); Assigned to Arm(s): N/A
D: Arm Label: NECT (Nifurtimox Eflornithine Combination Therapy); Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifurtimox, Drug: Eflornithine | Arm Label: Fexinidazole; Type: EXPERIMENTAL; Interventions: Drug: Fexinidazole | Intervention Type: DRUG; Name: Fexinidazole; Assigned to Arm(s): Fexinidazole | Intervention Type: DRUG; Name: Nifurtimox; Assigned to Arm(s): NECT (Nifurtimox Eflornithine Combination Therapy) | Intervention Type: DRUG; Name: Eflornithine; Assigned to Arm(s): NECT (Nifurtimox Eflornithine Combination Therapy)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Intermittent Versus Continuous Energy Restriction on Compensatory Mechanisms Activated During Weight Reduction
Brief Summary: Obesity has become a global epidemic with huge public health implications. Although clinical significant weight loss can be achieved by a combination of diet and behavioral modification, strong metabolic adaptations, with increased appetite and suppressed energy expenditure, are activated, which compromise weight loss maintenance and increase the risk of relapse. The aim of this project is to compare the effects of intermittent versus continuous energy restriction on the compensatory responses previously described using two low calory diets, with a similar macronutrient distribution. More specifically, this study will analyze, in the short-term, if an intermittent energy restricted diet is associated with less appetite and low reduction in energy expenditure when compared with a continuous energy restricted diet. This project can bring large practical benefits concerning the design of weight loss programs to minimize weight relapse.


Options:
A: Arm Label: TRF-b; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention B | Arm Label: TRF-d; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention D | Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention B; Assigned to Arm(s): TRF-b | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention D; Assigned to Arm(s): TRF-d
B: Arm Label: Fasting Day First; Type: OTHER; Interventions: Behavioral: Fasting First | Arm Label: Fed Day First; Type: OTHER; Interventions: Behavioral: Fed First | Intervention Type: BEHAVIORAL; Name: Fasting First; Assigned to Arm(s): Fasting Day First | Intervention Type: BEHAVIORAL; Name: Fed First; Assigned to Arm(s): Fed Day First
C: Arm Label: Intermittent Calorie Restriction; Type: EXPERIMENTAL; Interventions: Other: Calorie Restriction | Arm Label: Continuous Calorie Restriction; Type: EXPERIMENTAL; Interventions: Other: Calorie Restriction | Arm Label: Healthy Nutrition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Calorie Restriction; Assigned to Arm(s): Continuous Calorie Restriction, Intermittent Calorie Restriction
D: Arm Label: Intermittent energy restricted diet; Type: EXPERIMENTAL; Interventions: Behavioral: Intermittent energy restricted diet | Arm Label: Continuous energy restricted diet; Type: EXPERIMENTAL; Interventions: Behavioral: Continuous energy restricted diet | Intervention Type: BEHAVIORAL; Name: Intermittent energy restricted diet; Assigned to Arm(s): Intermittent energy restricted diet | Intervention Type: BEHAVIORAL; Name: Continuous energy restricted diet; Assigned to Arm(s): Continuous energy restricted diet

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients
Brief Summary: Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi


Options:
A: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA
B: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA
C: Arm Label: Riociguat (Adempas, BAY63-2521); Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: FDL 169 test formulation (Dose Level 1); Type: EXPERIMENTAL; Interventions: Drug: FDL169 | Arm Label: FDL 169 test formulation (Dose Level 2); Type: EXPERIMENTAL; Interventions: Drug: FDL169 | Arm Label: FDL 169 test formulation ( Dose Level 3); Type: EXPERIMENTAL; Interventions: Drug: FDL169 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FDL169; Assigned to Arm(s): FDL 169 test formulation ( Dose Level 3), FDL 169 test formulation (Dose Level 1), FDL 169 test formulation (Dose Level 2) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients
Brief Summary: Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi


Options:
A: Arm Label: TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TEZ/IVA, Drug: IVA, Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA, Drug: Placebo | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA, VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): VX-445/TEZ/IVA TC
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h
C: Arm Label: Riociguat (Adempas, BAY63-2521); Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients
Brief Summary: Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi


Options:
A: Arm Label: VX-770; Type: EXPERIMENTAL; Interventions: Drug: VX-770, Drug: Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): VX-770 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): VX-770
B: Arm Label: Riociguat (Adempas, BAY63-2521); Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: VX-770; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): VX-770
D: Arm Label: Ivacaftor; Type: ACTIVE_COMPARATOR; Interventions: Drug: ivacaftor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): Ivacaftor | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Chemotherapy with Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)
Brief Summary: This is a multicenter, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs. standard of care (observation alone in stage 1 and capecitabine and observation in stage 2) in patients after curative intent resection of BTC.


Options:
A: Arm Label: Test Group; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Apatinib | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Control Group, Test Group | Intervention Type: DRUG; Name: Apatinib; Assigned to Arm(s): Test Group
B: Arm Label: Cisplatin plus Gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin and Gemcitabine | Intervention Type: DRUG; Name: Cisplatin and Gemcitabine; Assigned to Arm(s): Cisplatin plus Gemcitabine
C: Arm Label: Gemcitabine plus Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine, Drug: Cisplatin | Arm Label: Capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Radiation: Concurrent Chemoradiotherapy, Drug: capecitabine, Drug: gemcitabine | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: capecitabine, Drug: gemcitabine | Intervention Type: RADIATION; Name: Concurrent Chemoradiotherapy; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): Arm 1, Arm 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EmPhAsIS: Empowering Pharmacists in Asthma Management Through Interactive SMS
Brief Summary: Between 8% and 12% of Canadians suffer from asthma. Although there are effective and inexpensive treatments, adherence to asthma treatment is amongst the lowest for all chronic diseases.The purpose of this study is to determine whether enhancing the role of community pharmacists in asthma management using interactive short messaging service (SMS) with asthma patients is a cost-effective model that will improve adherence to inhaled corticosteroid medications compared to usual care.


Options:
A: Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard care | Arm Label: Standard Care and Pharmaceutical Care; Type: OTHER; Interventions: Other: Standard care and Pharmaceutical care | Intervention Type: OTHER; Name: Standard care and Pharmaceutical care; Assigned to Arm(s): Standard Care and Pharmaceutical Care | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
B: Arm Label: TEAM Care; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacy TEAM monitoring and counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pharmacy TEAM monitoring and counseling; Assigned to Arm(s): TEAM Care
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Enhanced pharmacist care; Type: EXPERIMENTAL; Interventions: Other: Enhanced pharmacist care | Intervention Type: OTHER; Name: Enhanced pharmacist care; Assigned to Arm(s): Enhanced pharmacist care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Interactive SMS; Type: EXPERIMENTAL; Interventions: Other: Interactive SMS | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Interactive SMS; Assigned to Arm(s): Interactive SMS | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care

Answer: D